Ideaya Biosciences

Yahoo Finance • 4 days ago

IDEAYA slips on delaying results from darovasertib uveal melanoma trial

[Close up of the eye with carcinoma] flik47/iStock via Getty Images * IDEAYA Biosciences (IDYA [https://seekingalpha.com/symbol/IDYA]) is down ~5% in Monday trading after announcing it is delaying the release of topline results from a p... Full story

Yahoo Finance • 12 days ago

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

On February 17, 2026, Logos Global Management LP disclosed in a Securities and Exchange Commission filing that it bought 1,100,000 shares of Immunovant(NASDAQ:IMVT), an estimated $24.53 million trade based on quarterly average pricing. Lo... Full story

Yahoo Finance • 21 days ago

IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy.IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC On February 25, 2026, IDEAYA Biosciences, Inc. (NA... Full story

Yahoo Finance • 22 days ago

Notable Thursday Option Activity: MDB, SOC, IDYA

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in MongoDB Inc (Symbol: MDB), where a total of 34,692 contracts have traded so far, representing approximately 3.5 million underlying... Full story

Yahoo Finance • 3 months ago

Biotech Stocks Shine After Hours: Novo Nordisk, IDEAYA, Healthcare Triangle Among Gainers

(RTTNews) - Healthcare and biotechnology stocks saw notable moves in after-hours trading on Monday, with several companies posting strong gains despite limited news flow. Novo Nordisk A/S (NVO) surged in extended trading, climbing 9.48% t... Full story

Yahoo Finance • 3 months ago

IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma

Targeted enrollment of 435 patients to enable potential full approval filing has been completed in OptimUM-02 trial Topline data, including median PFS, are expected in 1Q 2026 to support a potential accelerated approval filing in the Unite... Full story

Yahoo Finance • 4 months ago

IDEAYA Secures IND Clearance For IDE034 In Solid Tumors

(RTTNews) - IDEAYA Biosciences, Inc. (IDYA), announced that the U.S. FDA has cleared its IND application for IDE034, a potential first-in-class bispecific B7H3/PTK7 TOP1 antibody-drug conjugate (ADC) for the treatment of multiple solid tum... Full story

Yahoo Finance • 4 months ago

IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Nov. 28, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on Novembe... Full story

Yahoo Finance • 7 months ago

10 most overbought S&P 500 stocks ahead of PPI and CPI data

[Top 10 alphabet letters top view on purple glitter background] Wall Street has started the week on a cautious tone as investors flag the most overbought stocks in the S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]), while broader... Full story

Yahoo Finance • 7 months ago

KNDS CEO is said to see 2026 IPO as 'realistic' path to expansion

[German tanks Leopard 2 parked on a street] Tramino KNDS, the Franco-German tankmaker behind the Leopard 2, is laying the groundwork for a potential initial public offering in 2026 as it looks to broaden its shareholder base and finance g... Full story

Yahoo Finance • 7 months ago

Biggest stock movers Monday: RAPP, HOUR, IDYA, NFE and more

[Shot of a handsome young businessman using a digital tablet while working late in his office] PeopleImages U.S. stock futures edged up on Monday as investors looked ahead to two important inflation reports this week, that will shape expe... Full story

Yahoo Finance • 7 months ago

Ideaya Biosciences gets coverage initiation at Barclays and Citizens

[Wall Street sign, New York City, USA] mbbirdy/E+ via Getty Images Ideaya Biosciences (NASDAQ:IDYA [https://seekingalpha.com/symbol/IDYA]) got coverage initiation from Barclays and Citizens, reflecting increasing confidence in the company... Full story

Yahoo Finance • 7 months ago

IDEAYA Biosciences Announces First-Patient-In for Phase 1/2 Combination Trial of IDE397, A Potential First-in-Class MAT2A Inhibitor, and Trodelvy® in MTAP-Deletion Non-Small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., Sept. 4, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have enrolled their first patient with non-small cell lung cancer (NSCL... Full story

Yahoo Finance • 7 months ago

IDEAYA Biosciences announces agenda for upcoming R&D day

NEW YORK - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a precision medicine company with a market capitalization of $2.1 billion that maintains a strong balance sheet with more cash than debt, has announced the agenda for its upcoming Research... Full story

Yahoo Finance • 8 months ago

Ideaya Biosciences earnings missed by $0.09, revenue topped estimates

Investing.com - Ideaya Biosciences (NASDAQ: IDYA) reported second quarter EPS of $-0.88, $0.09 worse than the analyst estimate of $-0.79. Revenue for the quarter came in at $6M versus the consensus estimate of $3.81M. Ideaya Biosciences’s... Full story

Yahoo Finance • 8 months ago

Bullish Two Hundred Day Moving Average Cross - IDYA

In trading on Wednesday, shares of IDEAYA Biosciences Inc (Symbol: IDYA) crossed above their 200 day moving average of $22.89, changing hands as high as $23.36 per share. IDEAYA Biosciences Inc shares are currently trading up about 5.5% o... Full story

Yahoo Finance • 8 months ago

IDEAYA Biosciences Announces 10-Year Anniversary R&D Day on September 8, 2025 to Present Multiple Clinical Data Updates and Outline Future Growth Strategy

SOUTH SAN FRANCISCO, Calif., July 23, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced it will host an in-per... Full story

Yahoo Finance • 8 months ago

Hengrui to present phase 1 data on DLL3-targeting lung cancer drug

JIANGSU, China - IDEAYA Biosciences, Inc. (NASDAQ:IDYA), a $1.9 billion market cap biotech company with a robust balance sheet showing more cash than debt, and Jiangsu Hengrui Pharmaceuticals announced Tuesday that clinical data for their... Full story

Yahoo Finance • 9 months ago

Ideaya Biosciences stock price target lowered to $30 by RBC Capital

Investing.com - RBC Capital lowered its price target on Ideaya Biosciences (NASDAQ:IDYA) to $30.00 from $57.00 on Wednesday, while maintaining an Outperform rating on the biopharmaceutical company. The stock, currently trading at $22.42, h... Full story

Yahoo Finance • last year

IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in t... Full story